Inhibitory Potency of C-glycosyl Flavonoids from<i>Morus</i>sp. on Advanced Glycation End Products

Anandan, Satish; Kotebagilu, Namratha Pai; Shivanna, Lohith Mysuru; Urooj, Asna

doi:10.1080/22311866.2017.1398680

Cited by 6 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our laboratory, varieties of M. indica have been screened for its proximate composition, phytochemical profile, antioxidant, anti-hypercholesterolemic, anti-cancer and anti-diabetic effect in in-vitro and ex-vivo models [20]. The earlier studies using the extract of M. indica has shown a potential anti-glycation effect in the BSA-glucose model [21]. Hence, the present study was aimed at the biosynthesis of ZnO-NPs from M. indica and to evaluate its inhibitory efficacy against AGEs formation.…”

Section: Introductionmentioning

confidence: 99%

Biosynthesized ZnO-NPs from Morus indica Attenuates Methylglyoxal-Induced Protein Glycation and RBC Damage: In-Vitro, In-Vivo and Molecular Docking Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

The development of advanced glycation end-products (AGEs) inhibitors is considered to have therapeutic potential in diabetic complications inhibiting the loss of the biomolecular function. In the present study, zinc oxide nanoparticles (ZnO-NPs) were synthesized from aqueous leaf extract of Morus indica and were characterized by various techniques such as ultraviolet (UV)-Vis spectroscopy, Powder X-Ray Diffraction (PXRD), Fourier Transform Infrared Spectroscopy (FT-IR), Scanning electron microscopy (SEM), and energy dispersive spectroscopy (EDS). Further, the inhibition of AGEs formation after exposure to ZnO-NPs was investigated by in-vitro, in-vivo, and molecular docking studies. Biochemical and histopathological changes after exposure to ZnO-NPs were also studied in streptozotocin-induced diabetic rats. ZnO-NPs showed an absorption peak at 359 nm with a purity of 92.62% and ~6–12 nm in size, which is characteristic of nanoparticles. The images of SEM showed agglomeration of smaller ZnO-NPs and EDS authenticating that the synthesized nanoparticles were without impurities. The biosynthesized ZnO-NPs showed significant inhibition in the formation of AGEs. The particles were effective against methylglyoxal (MGO) mediated glycation of bovine serum albumin (BSA) by inhibiting the formation of AGEs, which was dose-dependent. Further, the presence of MGO resulted in complete damage of biconcave red blood corpuscles (RBCs) to an irregular shape, whereas the morphological changes were prevented when they were treated with ZnO-NPs leading to the prevention of complications caused due to glycation. The administration of ZnO-NPs (100 mg Kg−1) in streptozotocin(STZ)-induced diabetic rats reversed hyperglycemia and significantly improved hepatic enzymes level and renal functionality, also the histopathological studies revealed restoration of kidney and liver damage nearer to normal conditions. Molecular docking of BSA with ZnO-NPs confirms that masking of lysine and arginine residues is one of the possible mechanisms responsible for the potent antiglycation activity of ZnO-NPs. The findings strongly suggest scope for exploring the therapeutic potential of diabetes-related complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Biosynthesized ZnO-NPs from Morus indica Attenuates Methylglyoxal-Induced Protein Glycation and RBC Damage: In-Vitro, In-Vivo and Molecular Docking Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Data from three replicates of each experiment were subjected to analysis of variance (ANOVA) using SPSS Inc. 16.0. Significant effects of treatments were determined by F values (p ≤ 0.05).…”

Section: Discussionmentioning

confidence: 99%

“…15 In our previous studies, extract of M. indica G4 variety has shown a potential anti-glycation effect in BSA-glucose model. 16 Further, the bioactive compounds of M. indica G4 variety were sequentially extracted, identified and quantified by UP-LCMS. Among them, apigenin (API) had the maximum yield and it was isolated by preparative HPLC and characterized by FTIR, NMR and SEM.…”

Section: Introductionmentioning

confidence: 99%

Ex vivo and in silico Molecular Docking Studies of Aldose Reductase Inhibitory Activity of Apigenin from Morus indica L.

Anandan¹,

Mahadevamurthy²,

Chandra³

et al. 2018

JYP

Self Cite

View full text Add to dashboard Cite

Objective: An investigation on Aldose Reductase Enzyme (ALR) inhibitory activity of apigenin (API) isolated from Morus indica L. was evaluated by ex vivo and molecular docking studies. Materials and Methods: The inhibitory efficacy of API from M. indica was evaluated against ALR in lens tissue of mice by ex vivo and their binding mechanism through molecular docking was carried out by AutoDock. Results: The API (10-50 µg mL -1 ) concentration exhibited significant inhibition (p ≤ 0.05) of ALR enzyme in a dose dependent manner with IC 50 value of 39.23 µg mL -1 . The positive control aminoguanidine (AG) at 10 mM inhibited 42.96% of ALR. The molecular docking studies revealed that API showed better binding energy (-9.15 kJ mol -1 ) when compared to AG (-3.78 kJ mol -1 ). Molecular interaction analysis showed that API interrupts the proton donation mechanism which is necessary for the catalytic activity of ALR by forming H-bond with Trp20 (proton donor). Conclusion: The ALR inhibition potential offered by API was further confirmed through molecular docking studies. The present findings support the pharmacological application of API for the treatment of diabetes cataract.This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

show abstract

“…MI is a non-toxic natural therapeutic plant used as herbal medicine as hypoglycaemic and diuretic [12] . In our previous studies, on 80 % methanol leaf extract of MI G4 variety (AQME), two C-glycosyl flavonoid compounds, apigenin and luteolin were detected [13] . The chemical constituents along with the above mentioned flavonoids of AQME exhibited strong metal-ion chelating and inhibitory effects of AGEs (bovine serum albumin, BSA-glucose model) in vitro.…”

Section: Fourier-transform Infrared (Ftir) Spectroscopymentioning

confidence: 91%

Bioactive Compounds from Morus indica as Inhibitors of Advanced Glycation End Products

An¹,

Urooj²

2019

pharmaceutical-sciences

View full text Add to dashboard Cite

Anandan and Urooj: Morus indica as Inhibitors of Advanced Glycation End ProductsThe present study aimed at identifying the active antiglycation constituents of G4 variety of Morus indica leaves. The bioactive compounds of G4 were identified and quantified using ultra-performance liquid chromatography/mass spectroscopy, isolated by preparative high performance liquid chromatography and characterized by Fourier-transform infrared spectroscopy, nuclear magnetic resonance and scanning electron microscopy. Based on results of the ultra-performance liquid chromatography/mass spectroscopy, extract with maximum bioactive compounds was chosen to study antiglycation property at different stages. The 80 % methanol extract of Morus indica leaves showed presence of 4 compounds, chlorogenic acid, ferulic acid, rutin and apigenin of which apigenin showed the maximum yield. This is the first report on the isolation of apigenin from the leaves of Morus indica G4 variety. Results obtained indicated that Morus indica leaf extract inhibited formation of advanced glycation end products. Also, scanning electron microscopy images indicated the protective effect against the formation of acanthocytes. These results provided evidence for the antiglycation effects of Morus indica leaves and suggested a potential role in management of diabetic complications.

show abstract

Inhibitory Potency of C-glycosyl Flavonoids fromMorussp. on Advanced Glycation End Products

Cited by 6 publications

References 20 publications

Biosynthesized ZnO-NPs from Morus indica Attenuates Methylglyoxal-Induced Protein Glycation and RBC Damage: In-Vitro, In-Vivo and Molecular Docking Study

Biosynthesized ZnO-NPs from Morus indica Attenuates Methylglyoxal-Induced Protein Glycation and RBC Damage: In-Vitro, In-Vivo and Molecular Docking Study

Ex vivo and in silico Molecular Docking Studies of Aldose Reductase Inhibitory Activity of Apigenin from Morus indica L.

Bioactive Compounds from Morus indica as Inhibitors of Advanced Glycation End Products

Contact Info

Product

Resources

About